Upstream Bio
Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.
Technology stack
detected 2026-06-07No comments yet. Be the first to share your take.
What does Upstream Bio do?
Upstream Bio is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory diseases. Their lead program is a monoclonal antibody designed to inhibit the TSLP receptor, a key upstream mediator in multiple inflammatory signaling pathways. By targeting TSLP, Upstream Bio aims to address a broad range of immune-mediated conditions.
How much funding has Upstream Bio raised?
Upstream Bio has raised a total of $450M in funding. The most recent round on record is Series B.
Where is Upstream Bio headquartered?
Upstream Bio is headquartered in Waltham, United States.
When was Upstream Bio founded?
Upstream Bio was founded in 2021.
What industry does Upstream Bio operate in?
Upstream Bio operates in Life Sciences, Therapeutics, Biotech, Drug Discovery, Clinical Trials, HealthTech.
How many employees does Upstream Bio have?
Upstream Bio has approximately 75 people on record.